Bate A (2000) "Validating" automated signal detection methods used in spontaneous reporting systems. In: 16th International Conference on Pharmacoepidemiology. Barcelona.

Bate A, et al. (1998a) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54: 315-21.

Bate A, et al. (1998b) Identifying and quantifying signals automatically. Pharmacoepidemiology and Drug Safety 7 (Suppl 2).

Bate A, Lindquist M, Orre R, Meyboom R, Edwards R (2000) Automated classification of signals as group effects or drug specific on the WHO database. In: 8th Annual Meeting European Society of Pharmacovigi-lance. Verona: Elsevier.

Bowdler J (1997) Effective Communications in Pharma-covigilance, Vol. 1, 1st edn. Birmingham, England: W. Lake Ltd.

CIOMS (1995) Harmonization of Data Fields for Electronic Transmission of Case-Report Information Internationally. Geneva: CIOMS.

Edwards IR (1997) Pharmacological basis for adverse drug reactions. In: Speight T, Holford N, eds., Avery's Drug Treatment. Auckland: Adis International Ltd, pp. 261-99.

Edwards IR (1999) Spontaneous reporting—of what? Clinical concerns about drugs. Br J Clin Pharmacol 48: 138-41.

Edwards IR (2000) The accelerating need for pharma-covigilance. J R Coll Phys Lond 34(1): 48-51.

Edwards IR, Biriell C (1994) Harmonisation in pharma-covigilance. Drug Safety 10: 93-102.

Edwards IR, Fucik H (1996) Impact and credibility of the WHO adverse reaction signals. Drug Inf J 30(2): 461 -4.

Edwards IR, Hugman B (1997) The challenge of effectively communicating risk-benefit information. Drug Safety 17(4): 216-27.

Edwards IR, Wiholm B-E, Martinez C (1996) Concepts in risk-benefit assessment. Drug Safety 15(1): 1-7.

Edwards IR, et al. (1990) Quality criteria for early signals of possible adverse drug reactions. Lancet 336: 156-8.

Edwards IR, et al. (1993a) Proposed improvement to the WHO Adverse Reaction Terminology (WHO-ART). Pharmacoepidemiology and Drug Safety 2: 177-84.

Edwards IR, et al. (1993b) Towards a new adverse event dictionary. Pharmacoepidemiology and Drug Safety 2: 175-6.

Edwards IR et al. (2000) Understanding and communication of key concepts in therapeutics. In: Moments of Truth—Communicating Drug Safety. Verona: Elsevier.

Farah MH (1998) Consumer protection and herbal remedies. WHO Drug Information 12(3): 141.

Farah MH. (2000a) Key issues in herbal pharmaco-vigilance. Adverse Drug Reactions J 2(2): 105-9.

Farah MH, et al. (2000b) International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiology and Drug Safety 9: 10512.

Lindquist M, Edwards IR (1993) Adverse drug reaction reporting in Europe: some problems of comparison. Int J Risk Safety Med 4: 35-46.

Lindquist M, Edwards IR (1997) Risks of non-sedating antihistamines. Lancet 349: 1322.

Lindquist M (1990) Uses and limitations of a global reporting pool. In: Meeting on Methods for the Detection and Study of Unwanted Drug Effect. Kiel, Germany, 26-29 Nov.

Lindquist M (1998) The WHO Programme for International Drug Monitoring: the present and future. In: Mitchard M, ed., Electronic Communication Technologies. pp. 527-49.

Lindquist M (2000) Signal detection using the WHO international database. In: 8th Annual Meeting European Society of Pharmacovigilance. Verona: Elsevier.

Lindquist M, et al. (1994) Pharmacovigilance information on an old drug—an international study of spontaneous reports on Digoxin. Drug Investigation 8: 73-80.

Lindquist M, et al. (1996) Omeprazole and visual disorders: seeing alternatives. Pharmacoepidemiology and Drug Safety 5: 27-32.

Lindquist M, et al. (1997) How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. Pharmacol Toxicol 80: 211-17.

Lindquist M, et al. (1999) From association to alert—a revised approach to international signal analysis. Pharmacoepidemiology and Drug Safety 8: S15 -S25.

Lindquist M, Farah MH, Edwards R (2000) Monitoring of herbal medicines. In: Clinical Pharmacology and Therapeutics. Florence: Blackwell.

Meyboom RHB (2000) The case for good pharmaco-vigilance practice. Pharmacoepidemiology and Drug Safety 9: 335-6.

Meyboom RHB, Lindquist M, Flygare AK, Biriell C, Edwards IR (2000a) Should therapeutic ineffectiveness be reported as an adverse drug reaction? In: 8th Annual Meeting European Society of Pharmacovigi-lance. Verona: Elsevier.

Meyboom RHB, Lindquist M, Flygare A-K, Biriell C, Edwards RI (2000b) The value of reporting therapeutic ineffectiveness as an adverse drug reaction. Drug Safety 23(2): 95-99.

Mills A, Edwards IR (1999) Venous thromboembolism and the pill. Human Reproduction 14(1): 7-10.

Olsson S, ed. (1997) National Pharmacovigilance Systems. Uppsala: Uppsala Monitoring Centre.

Orre R, et al. (2000) Bayesian neural networks with confidence estimations applied to data mining. Computational Statistics and Data Analysis 34(8): 473-93.

WHO and Uppsala Monitoring Centre (2000) Safety Monitoring of Medicinal Products. Uppsala: WHO and Uppsala Monitoring Centre.

Was this article helpful?

0 0
Drug Free Life

Drug Free Life

How To Beat Drugs And Be On Your Way To Full Recovery. In this book, you will learn all about: Background Info On Drugs, Psychological Treatments Statistics, Rehab, Hypnosis and Much MORE.

Get My Free Ebook

Post a comment